Abstract:BACKGROUND:Abnormal activation of the NF-κB pathway is closely related to tumorigenesis and chemoresistance. Therefore, microRNAs that possess the NF-κB inhibitory activity may provide novel targets for anti-cancer therapy. miR-26 family members have been shown to be frequently downregulated in hepatocellular carcinoma (HCC) and correlated with the poor survival of HCC patients. To date, there is no report disclosing the regulatory role of miR-26 on the NF-κB pathway and its biological significance.METHODS:The effects of miR-26b on the NF-κB signaling pathway and the chemosensitivity of cancer cells were examined in two HCC cell lines, QGY-7703 and MHCC-97H, using both gain- and loss-of-function studies. The correlation between miR-26b level and apoptosis rate was further investigated in clinical HCC specimens.RESULTS:Both TNFα and doxorubicin treatment activated the NF-κB signaling pathway in HCC cells. However, the restoration of miR-26b expression significantly inhibited the phosphorylation of IκBα and p65, blocked the nuclear translocation of NF-κB, reduced the NF-κB reporter activity, and consequently abrogated the expression of NF-κB target genes in TNFα or doxorubicin-treated HCC cells. Furthermore, the ectopic expression of miR-26b dramatically sensitized HCC cells to the doxorubicin-induced apoptosis, whereas the antagonism of miR-26b attenuated cell apoptosis. Consistently, the miR-26b level was positively correlated with the apoptosis rate in HCC tissues. Subsequent investigations revealed that miR-26b inhibited the expression of TAK1 and TAB3, two positive regulators of NF-κB pathway, by binding to their 3'-untranslated region. Moreover, knockdown of TAK1 or TAB3 phenocopied the effects of miR-26b overexpression.CONCLUSIONS:These data suggest that miR-26b suppresses NF-κB signaling and thereby sensitized HCC cells to the doxorubicin-induced apoptosis by inhibiting the expression of TAK1 and TAB3. Our findings highlight miR-26b as a potent inhibitor of the NF-κB pathway and an attractive target for cancer treatment.

Microrna-26 a Induces a Mitochondrial Apoptosis Mediated by P 53 Through Targeting to Inhibit Mcl 1 in Human Hepatocellular Carcinoma

Regulation of proliferation, angiogenesis and apoptosis in hepatocellular carcinoma by miR-26b-5p

Mcl-1 Is a Novel Target of miR-26b That Is Associated with the Apoptosis Induced by TRAIL in HCC Cells

MicroRNA-26a suppresses tumor growth and metastasis of human hepatocellular carcinoma by targeting interleukin-6-Stat3 pathway.

MiR-26 Enhances Chemosensitivity and Promotes Apoptosis of Hepatocellular Carcinoma Cells Through Inhibiting Autophagy

microRNA-26a suppresses recruitment of macrophages by down-regulating macrophage colony-stimulating factor expression through the PI3K/Akt pathway in hepatocellular carcinoma

A miRNA-mediated attenuation of hepatocarcinogenesis in both hepatocytes and Kupffer cells

Down-regulation of miR-26 a-5 p and its regulatory roles in hepatocellular carcinoma : an in silico analysis

Microrna-26a Suppresses Angiogenesis in Human Hepatocellular Carcinoma by Targeting Hepatocyte Growth Factor-Cmet Pathway

MicroRNA-26a Promotes Anoikis in Human Hepatocellular Carcinoma Cells by Targeting Alpha5 Integrin

Mir-26 Induces Apoptosis and Inhibits Autophagy in Non-small Cell Lung Cancer Cells by Suppressing TGF-β1-JNK Signaling Pathway

MicroRNA-26a Inhibits Proliferation and Metastasis of Human Hepatocellular Carcinoma by Regulating DNMT3B-MEG3 Axis.

MicroRNA-26b is underexpressed in human breast cancer and induces cell apoptosis by targeting SLC7A11.

MicroRNA-26b Suppresses the NF-κB Signaling and Enhances the Chemosensitivity of Hepatocellular Carcinoma Cells by Targeting TAK1 and TAB3

Mir-26A Promoted by Interferon-Alpha Inhibits Hepatocellular Carcinoma Proliferation and Migration by Blocking EZH2.

Down-regulation of Mir-26A-5p in Hepatocellular Carcinoma: A Qrt-Pcr and Bioinformatics Study

MicroRNA-26a Inhibits Angiogenesis by Down-Regulating VEGFA Through the PIK3C2α/Akt/HIF-1α Pathway in Hepatocellular Carcinoma.

Mir-26B Enhances the Sensitivity of Hepatocellular Carcinoma to Doxorubicin Via USP9X-dependent Degradation of P53 and Regulation of Autophagy

Pathologically Decreased Mir-26A Antagonizes Apoptosis and Facilitates Carcinogenesis by Targeting MTDH and EZH2 in Breast Cancer.

MicroRNA-26a Acts As a Tumor Suppressor Inhibiting Gallbladder Cancer Cell Proliferation by Directly Targeting HMGA2.

MicroRNA-26b Suppresses Tumorigenicity and Promotes Apoptosis in Small Cell Lung Cancer Cells by Targeting Myeloid Cell Leukemia 1 Protein